Improved time in range over 1 year is associated with reduced albuminuria in individuals with sensor-augmented insulin pump-treated type 1 diabetes
The DOI matches its Crossref record; 12 of the 13 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate the association between treatment-induced change in continuous glucose monitoring (CGM) time in range (TIR) and albuminuria in persons with type 1 diabetes (T1D) treated with sensor-augmented insulin pumps (SAP). RESEARCH DESIGN AND METHODS: Twenty-six out of 55 participants with albuminuria and multiple daily injection therapy (25% females; median 51 [interquartile range 46–63] years of age; glycated hemoglobin A1c (HbA1c) 75 [68–88] mmol/mol [9.0% (8.4–10.4%)]; and urinary albumin-to-creatinine ratio (UACR) 89 [37–250] mg/g) were in a randomized controlled trial assigned to SAP therapy for 1 year. Anthropometrics, CGM data, and blood and urine samples were collected every 3 months. RESULTS: Mean change (95% CI) in percentage of TIR (%TIR) was 13.2% (6.2; 20.2), in HbA1c was −14.4 (−17.4; −10.5) mmol/mol (−1.3% [−1.6; −1.0]), and in UACR was −15% (−38; 17) (all P < 0.05). UACR decreased by 19% (10; 28) per 10% increase in %TIR (P = 0.04), 18% (1; 30) per 10 mmol/mol decrease in HbA1c (P = 0.07), and 31% per 10-mmHg decrease in mean arterial pressure (P < 0.001). CONCLUSIONS: In this longitudinal study, treatment-induced increase in %TIR was significantly associated with decrease in albuminuria in T1D.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A 10-to 14-day CGM assessment of TIR, with CGM wear of 70% or higher, and other CGM metrics can be used to assess glycemic status and are useful in clinical management (22)(23)(24)(25)(26).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [24]
In the citing paper
“TIR is associated with microvascular complications (45,46), and a TIR of 70% roughly corresponds to an HbA 1c of 53 mmol/mol (7.0%).”
In the citing paper
“Although the evidence of HbA 1c reduction remains the most robust measure associated with chronic diabetes complications and is the only measure that is prospectively validated, more recent studies have begun to examine the relationship between time that glucose is within the target range and long-term complications and have provided the basis for glycemic targets with newer glucose monitoring”
In the citing paper
“Hypoglycemia with glucose levels below 3.0 mmol/L (54 mg/dL) occurs much more often than previously appreciated (46,101).”
Citations
Cites
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237
Self-citationInternational consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Self-citationValidation of Time in Range as an Outcome Measure for Diabetes Clinical Trials
Beck, R. W., Bergenstal, R. M., Riddlesworth, T. D., Kollman, C., Li, Z., Brown, A. S., & Close, K. L. (2019) · Diabetes Care · doi:10.2337/dc18-1444 · Cited by 793
Villena Gonzales, W., Mobashsher, A., & Abbosh, A. (2019) · Sensors · doi:10.3390/s19040800 · Cited by 772
The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group (2016) · Diabetes Care · doi:10.2337/dc15-1990 · Cited by 712
Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring
Bergenstal, R. M., Beck, R. W., Close, K. L., Grunberger, G., Sacks, D. B., Kowalski, A., Brown, A. S., Heinemann, L., Aleppo, G., Ryan, D. B., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1581 · Cited by 684
Mayeda, L., Katz, R., Ahmad, I., Bansal, N., Batacchi, Z., Hirsch, I. B., Robinson, N., Trence, D. L., Zelnick, L., & de Boer, I. H. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000991 · Cited by 162
Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring
Xing, D., Kollman, C., Beck, R. W., Tamborlane, W. V., Laffel, L., Buckingham, B. A., Wilson, D. M., Weinzimer, S., Fiallo-Scharer, R., & Ruedy for the Juvenile Diabetes Research Foundation Continuo, K. J. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0156 · Cited by 131
Yoo, J. H., Choi, M. S., Ahn, J., Park, S. W., Kim, Y., Hur, K. Y., Jin, S.-M., Kim, G., & Kim, J. H. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0499 · Cited by 98
Glycated Hemoglobin, Plasma Glucose, and Erythrocyte Aging
del Río, M. B., Tiwari, M., Amodu, L., Cagliani, J. A., & Rilo, H. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816659885 · Cited by 46
Rosenlund, S., Hansen, T. W., Rossing, P., & Andersen, S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2839 · Cited by 19
Self-citation
Cited by
6. Glycemic Targets: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s006 · Cited by 1,403
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699
“TIR is associated with microvascular complications (45,46), and a TIR of 70% roughly corresponds to an HbA1c of 53 mmol/mol (7.”
Self-citation6. Glycemic Targets: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s006 · Cited by 684
6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s006 · Cited by 486
6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s006 · Cited by 440
Metadata
- Authors
- Ranjan, A. G., Rosenlund, S. V., Hansen, T. W., Rossing, P., Andersen, S., & Nørgaard, K.
- Affiliations
- Danish Diabetes Academy (DK)
- Steno Diabetes Center Copenhagen (DK)
- University of Copenhagen (DK)
- Corresponding author
- Ranjan, Ajenthen G.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-09-04
- Volume
- 43
- Issue
- 11
- Pages
- 2882-2885
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W3083350156
- Cited by
- 72
- References
- 13
- Citations by year
- 2026: 7 · 2025: 6 · 2024: 8 · 2023: 13 · 2022: 17 · 2021: 20 · 2020: 1
- FWCI
- 9.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Danish Diabetes Academy (PD002-19)
- Danish Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- time in range, albuminuria, type 1 diabetes, sensor-augmented insulin pump therapy, continuous glucose monitoring, albumin-creatinine ratio, HbA1c, mean arterial pressure, glycemic control, diabetic nephropathy
- MeSH terms
- Serum Albumin, Human, Albuminuria, Blood Glucose, Creatinine, Diabetes Mellitus, Type 1, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Longitudinal Studies, Male, Middle Aged, Time Factors, Blood Glucose Self-Monitoring, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.